Demographic characteristics and HIV/STI prevalence among female sex workers attending Melbourne Sexual Health Centre, 2015–2017.
| Year | Ptrend | |||
| 2015* | 2016 | 2017 | ||
| Number of consultations | 2282 | 2986 | 3270 | – |
| Number of individuals | 1297 | 1503 | 1641 | – |
| Demographic characteristics† | ||||
| Age, mean±SD | 32.7±8.5 | 32.3±8.6 | 32.2±8.8 | 0.111 |
| Country of birth, n (%) | ||||
| Australia | 491 (37.9%) | 605 (40.3%) | 672 (41.0%) | 0.347 |
| Overseas | 739 (57.0%) | 812 (54.0%) | 890 (54.2%) | |
| Unknown | 67 (5.2%) | 86 (5.7%) | 79 (4.8%) | |
| Language spoken at home, n (%) | ||||
| English | 806 (62.1%) | 952 (63.3%) | 1010 (61.5%) | 0.007 |
| Chinese | 134 (10.3%) | 150 (10.0%) | 235 (14.3%) | |
| Thai | 92 (7.1%) | 91 (6.1%) | 83 (5.1%) | |
| Korean | 79 (6.1%) | 88 (5.9%) | 89 (5.4%) | |
| Other | 103 (7.9%) | 127 (8.4%) | 139 (8.5%) | |
| Unknown | 83 (6.4%) | 95 (6.3%) | 85 (5.2%) | |
| HIV/STI prevalence, n/N (%)‡ | ||||
| Genital gonorrhoea | 11/2157 (0.5%) | 33/2830 (1.2%) | 34/3094 (1.1%) | 0.047 |
| Genital chlamydia | 47/2190 (2.1%) | 82/2850 (2.9%) | 98/3104 (3.2%) | 0.031 |
| Oropharyngeal gonorrhoea | – | – | 59/2883 (2.0%) | – |
| Oropharyngeal chlamydia | – | – | 61/2878 (2.1%) | – |
| HIV | 3/2147 (0.1%) | 3/2763 (0.1%) | 7/3027 (0.2%) | 0.375 |
| Syphilis | 4/2143 (0.2%) | 1/2763 (0.2%) | 3/3028 (0.1%) | 0.403 |
*Only included data from the 23 March to 31 December 2015.
†Age, country of birth and language spoken at home were calculated based on the number of individuals per year. Independent samples t-test was used to assess the difference of mean age over the study period. χ2 test was used to assess the difference of country of birth over the study period.
‡HIV and STI prevalence was calculated based on the number of consultations per year. χ2 trend test was used to assess the trend of HIV/STI prevalence over the study period. N represents the number of tests performed and n represents the number of tests tested positive by nucleic acid amplification test using the Aptima Combo 2 Assay (Hologic, California, USA).